⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677524 | 0.71 | — | — | |
| Bromide SCHEMBL7030389 | 0.69 | — | — | |
| SCHEMBL24499224 | 0.67 | — | — | |
| SCHEMBL2586706 | 0.67 | — | — | |
| SCHEMBL3160786 | 0.67 | — | — | |
| SCHEMBL3012280 | 0.67 | — | — | |
| SCHEMBL5634287 | 0.67 | — | — | |
| SCHEMBL9967679 | 0.63 | — | — | |
| SCHEMBL13556075 | 0.63 | — | — | |
| SCHEMBL12244444 | 0.63 | HPGD (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | claimed |
| EP-3154547-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | Yuma Therapeutics, Inc. (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015192119-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| US-20050239841-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| WO-2005051381-A1 | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | claimed |
| US-20210363154-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2021-11-25 | — | — | US | disclosed |
| CN-106687114-B | Pyrimidine compounds and methods of use thereof | 尤马治疗公司 | 2021-08-31 | — | — | CN | disclosed |
| US-10961254-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10336768-B2 | Pyrimidine compounds and methods using the same | YUMA THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170107228-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| EP-3154547-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | Yuma Therapeutics, Inc. (US) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015192119-A1 | PYRIMIDINE COMPOUNDS AND METHODS USING THE SAME | YUMA THERAPEUTICS, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | RENOVIS, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060106074-A1 | ER-B-SELECTIVE LIGANDS | ASTRAZENECA AB (SE) | 2006-05-18 | — | — | US | disclosed |
| US-20060040988-A1 | Cox-2 Inhibiting pyridine derivatives | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| US-20050239841-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005051381-A1 | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) | BIOVITRUM AB (SE) | 2005-06-09 | — | — | WO | disclosed |
| EP-1478631-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003045930-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| CN-1206423-A | Peptide derivatives of Dolastatin 15 and their use | BASF AG (DE) | 1999-01-27 | — | — | CN | disclosed |